Ionis Pharmaceuticals Inc (IONS) stock
Close on Nov 17, 2026Market cap $4.48BP/E –Yield –
Earnings
Ionis Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ionis Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | $243.00M | +54.8% | -$0.66 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | $268.00M | -40.7% | -$0.69 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $203.00M | – | -$1.41 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025before the open | $157.00M | – | -$0.80 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025during market hours | $452.00M | +100.9% | $0.70 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025during market hours | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 19, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024during market hours | $225.00M | +19.7% | -$0.45 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $119.00M | -9.2% | -$0.98 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 21, 2024during market hours | $325.00M | +113.8% | -$0.06 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $144.00M | – | -$1.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | $188.00M | +40.3% | -$0.60 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023during market hours | $131.00M | -7.7% | -$0.87 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023during market hours | $152.00M | -65.5% | -$0.37 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022during market hours | – | – | -$0.33 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022during market hours | $134.00M | – | -$0.74 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $142.00M | – | -$0.46 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022during market hours | $440.00M | – | $1.41 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021during market hours | $133.00M | – | -$0.58 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ionis Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| product sales | FY2026 | $100.00M – $110.00M | – | New | Jul 29, 2026 |
| TRYNGOLZA product sales, net | FY2026 | $50.00M | $800.00M – $825.00M | Lowered | Nov 9, 2026 |
| Operating loss on a non-GAAP basisnon-GAAP | FY2026 | $425.00M – $475.00M | $500.00M – $550.00M | Lowered | Nov 9, 2026 |
| Cash, cash equivalents and short-term investments | FY2026 | $1.60B | $1.60M | Raised | Nov 9, 2026 |
Guidance history
Every forecast Ionis Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Operating loss on a non-GAAP basis | FY2026 | $425.00M – $475.00M | Lowered |
| Nov 9, 2026 | Cash, cash equivalents and short-term investments | FY2026 | $1.60B | Raised |
| Nov 9, 2026 | TRYNGOLZA product sales, net | FY2026 | $50.00M | Lowered |
| Nov 9, 2026 | DAWNZERA product sales, net | FY2026 | $110.00M – $120.00M | Raised |
| Nov 9, 2026 | Total Revenue | FY2026 | $875.00M – $900.00M | Raised |
| Jul 29, 2026 | product sales | FY2026 | $100.00M – $110.00M | New |
| Jul 29, 2026 | product sales | FY2026 | $110.00M – $120.00M | Raised |
| Feb 25, 2026 | Operating loss on a non-GAAP basis | FY2026 | $500.00M – $550.00M | New |
| Feb 25, 2026 | Cash, cash equivalents and short-term investments | FY2026 | $1.60M | New |
| Feb 25, 2026 | Revenue | FY2026 | $800.00M – $825.00M | New |
| Oct 29, 2025 | Operating loss on a non-GAAP basis | FY2025 | -$300.00M – -$275.00M | New |
| Oct 29, 2025 | Cash, cash equivalents and short-term investments | FY2025 | $2.10B | New |
| Oct 29, 2025 | Total Revenue | FY2025 | $875.00M – $900.00M | New |
| Oct 29, 2025 | TRYNGOLZA product sales, net | FY2025 | $85.00M – $95.00M | Lowered |
| Jul 30, 2025 | Operating loss on a non-GAAP basis | FY2025 | $300.00M – $325.00M | Lowered |
| Jul 30, 2025 | Cash, cash equivalents and short-term investments | FY2025 | $2.00B | Raised |
| Jul 30, 2025 | TRYNGOLZA product sales, net | FY2025 | $75.00M – $80.00M | Lowered |
| Jul 30, 2025 | Total Revenue | FY2025 | $825.00M – $850.00M | Raised |
| Apr 30, 2025 | Operating loss on a non-GAAP basis | FY2025 | $375.00M | New |
| Apr 30, 2025 | Cash, cash equivalents and short-term investments | FY2025 | $1.90B | New |
| Apr 30, 2025 | Revenue | FY2025 | $725.00M – $750.00M | New |
| Nov 6, 2024 | cash, cash equivalents and short-term investments | FY2024 | $2.20B | Raised |
| Aug 1, 2024 | cash, cash equivalents and short-term investments | FY2024 | $1.70B | Reaffirmed |
| Feb 21, 2024 | Operating loss on a non-GAAP basis | FY2024 | $475.00M | New |
| Feb 21, 2024 | Cash, cash equivalents and short-term investments | FY2024 | $1.70B | New |
| Feb 21, 2024 | Revenue | FY2024 | $575.00M | New |
| Feb 22, 2023 | Net operating loss on a non-GAAP basis | FY2023 | $425.00M | New |
| Feb 22, 2023 | Cash, cash equivalents and short-term investments | FY2023 | $2.00B | New |
| Feb 22, 2023 | Operating expenses on a non-GAAP basis | FY2023 | $970.00M – $995.00M | New |
| Feb 22, 2023 | Revenue | FY2023 | $575.00M | New |
| Nov 9, 2022 | R&D expenses | FY2022 | +25% – +30% | New |
| Nov 9, 2022 | Cash, cash equivalents and short-term investments | FY2022 | $2.00B | New |
| Nov 9, 2022 | Operating expenses on a non-GAAP basis | FY2022 | $825.00M – $850.00M | Lowered |
| Nov 9, 2022 | Net loss on a non-GAAP basis | FY2022 | $275.00M | Lowered |
| Nov 9, 2022 | Revenue | FY2022 | $575.00M | New |
| Feb 24, 2022 | Operating Expenses (1) | FY2022 | $825.00M – $850.00M | New |
| Feb 24, 2022 | Net Loss (1) | FY2022 | $275.00M | Lowered |
| Feb 24, 2022 | Cash and Short-Term Investments | FY2022 | $1.70B | Raised |
| Feb 24, 2022 | Revenue | FY2022 | $575.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ionis Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Results
See a number that looks wrong?